157126-75-5

Upstream product

• 1643-29-4 3-(4-iodophenyl)propionic acid 
• 34633-08-4 ethyl 3-(4-iodophenyl)acrylate 
• 16004-15-2 1-bromomethyl-4-iodobenzene 
• 501-52-0 3-Phenylpropionic acid 

Downstream Products

• 60075-78-7 3-(p-iodophenyl)-propanol 
• 172483-74-8 1-bromo-3-(4'-iodophenyl)propane 
• 1597430-42-6 3-(4-iodophenyl)propyloxyamine hydrochloride 
• 1597430-58-4 C₁₈H₂₂IN₃O₆ 
• 737825-20-6 ethyl 4-(4-iodophenyl)-2-oxobutanoate 
• 737825-25-1 N-{5-(4-iodobenzyl)-4-[2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide 
• 1443744-28-2 C₁₃H₁₃IN₂O₂S 
• 737825-19-3 methyl 4-({2-(acetylamino)-4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-5-yl}methyl)benzoate hydrochloride 
• 737825-29-5 methyl 4-[(2-(acetylamino)-4-{2-[4-({(Z)-[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}-amino)phenyl]ethyl}-1,3-thiazol-5-yl)methyl]benzoate 
• 737825-28-4 methyl 4-({2-(acetylamino)-4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-5-yl}methyl)benzoate 
• 737825-27-3 N-{5-(4-(methoxycarbonyl)benzyl)-4-[2-(4-nitrophenyl)vinyl]-1,3-thiazol-2-yl}acetamide 
• 737825-24-0 N-[4-formyl-5-(4-iodobenzyl)-1,3-thiazol-2-yl]acetamide 
• 737825-23-9 ethyl 2-(acetylamino)-5-(4-iodobenzyl)-1,3-thiazole-4-carboxylate 
• 737825-22-8 ethyl 2-amino-5-(4-iodobenzyl)-1,3-thiazole-4-carboxylate hydrobromide 

Relevant academic research and scientific papers

Synthetic method of triazole compound

The invention discloses a synthetic method of a triazole compound N-((5-(4-iodophenyl)-2H-1,2,4-triazol-3-yl)methyl)-N-propylpropan-1-amine. The preparation method comprises the steps of carrying out reduction, acylation, imidization, ring closure, Boc removal and alkylation reaction on a starting raw material: 3-(4-iodophenyl)ethyl acrylate, so as to obtain a target product 7. The triazole compound is used as a template micromolecule for synthesizing various compound libraries.

4-alkyloxyimino derivatives of uridine-5′-triphosphate: Distal modification of potent agonists as a strategy for molecular probes of P2Y 2, P2Y4, and P2Y6 receptors

Extended N4-(3-arylpropyl)oxy derivatives of uridine-5′-triphosphate were synthesized and potently stimulated phospholipase C stimulation in astrocytoma cells expressing G protein-coupled human (h) P2Y receptors (P2YRs) activated by UTP (P2Y2/4R) or UDP (P2Y6R). The potent P2Y4R-selective N4-(3- phenylpropyl)oxy agonist was phenyl ring-substituted or replaced with terminal heterocyclic or naphthyl rings with retention of P2YR potency. This broad tolerance for steric bulk in a distal region was not observed for dinucleoside tetraphosphate agonists with both nucleobases substituted. The potent N 4-(3-(4-methoxyphenyl)-propyl)oxy analogue 19 (EC50: P2Y2R, 47 nM; P2Y4R, 23 nM) was functionalized for chain extension using click tethering of fluorophores as prosthetic groups. The BODIPY 630/650 conjugate 28 (MRS4162) exhibited EC50 values of 70, 66, and 23 nM at the hP2Y2/4/6Rs, respectively, and specifically labeled cells expressing the P2Y6R. Thus, an extended N4-(3- arylpropyl)oxy group accessed a structurally permissive region on three G q-coupled P2YRs, and potency and selectivity were modulated by distal structural changes. This freedom of substitution was utilized to design of a pan-agonist fluorescent probe of a subset of uracil nucleotide-activated hP2YRs.

Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia

α-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula STR1 wherein R2 is OR5 or R5a ; R3 and R5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.